1
|
Berry F, Morin‐Dewaele M, Majidipur A, Jamet T, Bartier S, Ignjatovic E, Toniutti D, Gaspar Lopes J, Soyeux‐Porte P, Maillé P, Saldana C, Brillet R, Ahnou N, Softic L, Couturaud B, Huet É, Ahmed‐Belkacem A, Fourati S, Louis B, Coste A, Béquignon É, de la Taille A, Destouches D, Vacherot F, Pawlotsky J, Firlej V, Bruscella P. Proviral role of human respiratory epithelial cell-derived small extracellular vesicles in SARS-CoV-2 infection. J Extracell Vesicles 2022; 11:e12269. [PMID: 36271885 PMCID: PMC9587708 DOI: 10.1002/jev2.12269] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 07/20/2022] [Accepted: 09/14/2022] [Indexed: 11/06/2022] Open
Abstract
Small Extracellular Vesicles (sEVs) are 50-200 nm in diameter vesicles delimited by a lipid bilayer, formed within the endosomal network or derived from the plasma membrane. They are secreted in various biological fluids, including airway nasal mucus. The goal of this work was to understand the role of sEVs present in the mucus (mu-sEVs) produced by human nasal epithelial cells (HNECs) in SARS-CoV-2 infection. We show that uninfected HNECs produce mu-sEVs containing SARS-CoV-2 receptor ACE2 and activated protease TMPRSS2. mu-sEVs cleave prefusion viral Spike proteins at the S1/S2 boundary, resulting in higher proportions of prefusion S proteins exposing their receptor binding domain in an 'open' conformation, thereby facilitating receptor binding at the cell surface. We show that the role of nasal mu-sEVs is to complete prefusion Spike priming performed by intracellular furin during viral egress from infected cells. This effect is mediated by vesicular TMPRSS2 activity, rendering SARS-CoV-2 virions prone to entry into target cells using the 'early', TMPRSS2-dependent pathway instead of the 'late', cathepsin-dependent route. These results indicate that prefusion Spike priming by mu-sEVs in the nasal cavity plays a role in viral tropism. They also show that nasal mucus does not protect from SARS-CoV-2 infection, but instead facilitates it.
Collapse
Affiliation(s)
- François Berry
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Margot Morin‐Dewaele
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Amene Majidipur
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Thibaud Jamet
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Sophie Bartier
- Department of ENT and Cervico‐Facial SurgeryAP‐HP, Centre Hospitalier Intercommunal de CréteilCréteilFrance,Department of ENT and Cervico‐Facial SurgeryAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance,Department of PulmonologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance,Institut Mondor de Recherche Biomédicale, INSERM U955, CNRS EMR 7000, Team “Biomechanics and Respiratory System”Univ Paris Est CreteilCréteilFrance
| | - Eva Ignjatovic
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Donatella Toniutti
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Jeanne Gaspar Lopes
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Pascale Soyeux‐Porte
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Pascale Maillé
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance,Department of PathologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance
| | - Carolina Saldana
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance,Department of OncologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance
| | - Rozenn Brillet
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Nazim Ahnou
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Laurent Softic
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Benoit Couturaud
- Institute of Chemistry and Materials (ICMPE)Univ Paris Est Creteil, CNRS UMR7182CréteilFrance
| | - Éric Huet
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Abdelhakim Ahmed‐Belkacem
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| | - Slim Fourati
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance,Department of VirologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance
| | - Bruno Louis
- Institut Mondor de Recherche Biomédicale, INSERM U955, CNRS EMR 7000, Team “Biomechanics and Respiratory System”Univ Paris Est CreteilCréteilFrance
| | - André Coste
- Department of ENT and Cervico‐Facial SurgeryAP‐HP, Centre Hospitalier Intercommunal de CréteilCréteilFrance,Department of ENT and Cervico‐Facial SurgeryAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance,Department of PulmonologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance,Institut Mondor de Recherche Biomédicale, INSERM U955, CNRS EMR 7000, Team “Biomechanics and Respiratory System”Univ Paris Est CreteilCréteilFrance
| | - Émilie Béquignon
- Department of ENT and Cervico‐Facial SurgeryAP‐HP, Centre Hospitalier Intercommunal de CréteilCréteilFrance,Department of ENT and Cervico‐Facial SurgeryAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance,Department of PulmonologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance,Institut Mondor de Recherche Biomédicale, INSERM U955, CNRS EMR 7000, Team “Biomechanics and Respiratory System”Univ Paris Est CreteilCréteilFrance
| | - Alexandre de la Taille
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance,Department of UrologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance
| | - Damien Destouches
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Francis Vacherot
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Jean‐Michel Pawlotsky
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance,Department of VirologyAP‐HP, Centre Hospitalier Universitaire Henri MondorCréteilFrance
| | - Virginie Firlej
- Team “Therapeutic Resistance in Prostate Cancer” (TRePCa)Univ Paris Est CreteilCréteilFrance
| | - Patrice Bruscella
- Institut Mondor de Recherche Biomédicale, INSERM U955, Team “Viruses, Hepatology, Cancer”Univ Paris Est CreteilCréteilFrance
| |
Collapse
|
2
|
Fourati S, Robin C, Rodriguez C, Leclerc M, Beckerich F, Pawlotsky J, Redjoul R, Maury S. Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation. eJHaem 2022; 3:980-982. [PMID: 35941883 PMCID: PMC9349499 DOI: 10.1002/jha2.512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 05/24/2022] [Accepted: 06/01/2022] [Indexed: 11/10/2022]
Affiliation(s)
- Slim Fourati
- Virology Department Assistance Publique‐Hôpitaux de Paris (AP‐HP) Henri Mondor Hospital Créteil France
- INSERM U955 Paris Est Créteil University UPEC Créteil France
| | - Christine Robin
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Christophe Rodriguez
- Virology Department Assistance Publique‐Hôpitaux de Paris (AP‐HP) Henri Mondor Hospital Créteil France
- INSERM U955 Paris Est Créteil University UPEC Créteil France
| | - Mathieu Leclerc
- INSERM U955 Paris Est Créteil University UPEC Créteil France
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Florence Beckerich
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Jean‐Michel Pawlotsky
- Virology Department Assistance Publique‐Hôpitaux de Paris (AP‐HP) Henri Mondor Hospital Créteil France
- INSERM U955 Paris Est Créteil University UPEC Créteil France
| | - Rabah Redjoul
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Sébastien Maury
- INSERM U955 Paris Est Créteil University UPEC Créteil France
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| |
Collapse
|
3
|
Firlej V, Majidipur A, Berry F, Soyeux P, Destouches D, Huet E, Pawlotsky J, Vacherot F, Bruscella P, De la Taille A. Régulation de TMPRSS2 par la voie des androgènes et implications dans l’infection SARS-CoV-2. Prog Urol 2021. [PMCID: PMC8557089 DOI: 10.1016/j.purol.2021.08.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Objectifs TMPRSS2 est une protéase cellulaire régulée par les androgènes dans les cellules prostatiques. L’entrée de SARS-CoV2 par fusion membranaire dans les cellules pulmonaires nécessite le clivage de Spike par TMPRSS2. Notre hypothèse est que le niveau des androgènes et la présence du récepteur des androgènes (RA) dans les cellules pulmonaires pourrait réguler l’expression de TMPRSS2 et influencerait l’entrée de SARS-CoV-2. Méthodes Les régulations de TMPRSS2 et du RA ont été étudiées dans deux lignées cellulaires pulmonaires (A549 et Calu-3) et dans des lignées de cellules prostatiques contrôles (LNCaP ou VCaP) grâce à des expériences de privation et de supplémentation en androgènes ainsi que par utilisation d’un siRNA ciblant le RA. La régulation de l’expression de ces deux gènes a été étudiée par RT-qPCR et Western blot. L’infection de SARS-CoV2 dans les cellules Calu-3 a été étudiée en condition de blocage du RA. Résultats Les études cliniques semblent montrer que les patients atteints de cancer de la prostate sous hormonothérapie ont une incidence plus faible d’infection par le SARS-CoV2 suggérant le rôle du RA dans l’infection du virus. Nos résultats montrent que les deux lignées de cellules pulmonaires utilisées (A549 et Calu-3) expriment TMPRSS2 et le RA au niveau ARNm et protéique. Dans ces lignées, il existe également une régulation de l’expression de TMPRSS2 et du RA par les androgènes. Cet effet est connu et bien retrouvé pour les lignées prostatiques. Enfin, nous avons pu montrer qu’au niveau des cellules pulmonaires, le taux d’infection par le SARS-CoV2 était moins important lorsque la voie du RA a été au préalable bloquée. Conclusion Le blocage de TMPRSS2 permettrait de limiter l’infection du virus. Nos résultats suggèrent que l’expression de TMPRSS2 est régulée par les androgènes dans des cellules pulmonaires et que la testostérone pourrait jouer un rôle dans l’infection du SARS-CoV2. Le blocage du RA serait donc une option thérapeutique envisagée pour limiter la COVID-19.
Collapse
|
4
|
Woerther P, Surgers L, Lamoureux C, Lepeule R, Demontant V, Gricourt G, Pawlotsky J, Rodriguez C. Diagnostic microbiologique pan-pathogène par métagénomique clinique, retour d’expérience en routine. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Jensen SB, Fahnøe U, Pham LV, Serre SBN, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky J, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology 2019; 70:771-787. [PMID: 30964552 PMCID: PMC6772116 DOI: 10.1002/hep.30647] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 04/03/2019] [Indexed: 12/26/2022]
Abstract
Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to control HCV. Here, we investigated patterns of PI resistance-associated substitutions (RASs) for the major HCV genotypes and viral determinants for persistence of key RASs. We identified protease position 156 as a RAS hotspot for genotype 1-4, but not 5 and 6, escape variants by resistance profiling using PIs grazoprevir and paritaprevir in infectious cell culture systems. However, except for genotype 3, engineered 156-RASs were not maintained. For genotypes 1 and 2, persistence of 156-RASs depended on genome-wide substitution networks, co-selected under continued PI treatment and identified by next-generation sequencing with substitution linkage and haplotype reconstruction. Persistence of A156T for genotype 1 relied on compensatory substitutions increasing replication and assembly. For genotype 2, initial selection of A156V facilitated transition to 156L, persisting without compensatory substitutions. The developed genotype 1, 2, and 3 variants with persistent 156-RASs had exceptionally high fitness and resistance to grazoprevir, paritaprevir, glecaprevir, and voxilaprevir. A156T dominated in genotype 1 glecaprevir and voxilaprevir escape variants, and pre-existing A156T facilitated genotype 1 escape from clinically relevant combination treatments with grazoprevir/elbasvir and glecaprevir/pibrentasvir. In genotype 1 infected patients with treatment failure and 156-RASs, we observed genome-wide selection of substitutions under treatment. Conclusion: Comprehensive PI resistance profiling for HCV genotypes 1-6 revealed 156-RASs as key determinants of high-level resistance across clinically relevant PIs. We obtained in vitro proof of concept for persistence of highly fit genotype 1-3 156-variants, which might pose a threat to clinically relevant combination treatments.
Collapse
Affiliation(s)
- Sanne Brun Jensen
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Ulrik Fahnøe
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Long V. Pham
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Stéphanie Brigitte Nelly Serre
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Qi Tang
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Lubna Ghanem
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Martin Schou Pedersen
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
- Department of Clinical MicrobiologyCopenhagen University HospitalHvidovreDenmark
| | - Santseharay Ramirez
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Daryl Humes
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Anne Finne Pihl
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Jonathan Filskov
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Christina Søhoel Sølund
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
- Department of Infectious DiseasesCopenhagen University HospitalHvidovreDenmark
| | - Julia Dietz
- Department of Internal Medicine 1University Hospital Frankfurt, and German Center for Infection Research, External Partner SiteFrankfurtGermany
| | - Slim Fourati
- National Reference Center for Viral Hepatitis B, C and D, Department of VirologyHenri Mondor Hospital, University of Paris‐Est, and INSERM U955CréteilFrance
| | - Jean‐Michel Pawlotsky
- National Reference Center for Viral Hepatitis B, C and D, Department of VirologyHenri Mondor Hospital, University of Paris‐Est, and INSERM U955CréteilFrance
| | - Christoph Sarrazin
- Department of Internal Medicine 1University Hospital Frankfurt, and German Center for Infection Research, External Partner SiteFrankfurtGermany
- Medizinische Klinik II, St. Josefs‐HospitalWiesbadenGermany
| | - Nina Weis
- Department of Infectious DiseasesCopenhagen University HospitalHvidovreDenmark
- Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Kristian Schønning
- Department of Clinical MicrobiologyCopenhagen University HospitalHvidovreDenmark
- Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Henrik Krarup
- Department of Molecular DiagnosticsAalborg University HospitalAalborgDenmark
| | - Jens Bukh
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Judith Margarete Gottwein
- Copenhagen Hepatitis C Program (CO‐HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| |
Collapse
|
6
|
Almarzooqi S, van Tilborg M, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Duarte-Rojo A, Kowgier M, Janssen HL, de Knegt R, Pawlotsky J, Cloherty G, Sarrazin C, Wedemeyer H, Feld J. A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS? J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy008.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - M van Tilborg
- Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
| | - R Maan
- Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
| | - J Vermehren
- Department of Gastroenterology and Hepatology, Goethe-University Hospital Frankfurt, Franfurt, Germany
| | - B Maasoumy
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - T Mazzulli
- University of Toronto, Toronto, ON, Canada
| | - A Duarte-Rojo
- University of Arkansas Medical Sciences, Arkansas, AR
| | - M Kowgier
- University of Toronto, Toronto, ON, Canada
| | | | - R de Knegt
- Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
| | - J Pawlotsky
- Hôpital Henri Mondor, National Reference Center for Viral Hepatitis B, C and Delta, Créteil, France
| | | | - C Sarrazin
- Department of Gastroenterology and Hepatology, Goethe-University Hospital Frankfurt, Franfurt, Germany
| | - H Wedemeyer
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - J Feld
- Medicine, University Health Network University of Toronto, Toronto, ON, Canada
| |
Collapse
|
7
|
Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky J. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017; 37:5-18. [PMID: 27473533 PMCID: PMC5216450 DOI: 10.1111/liv.13212] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Accepted: 07/26/2016] [Indexed: 12/11/2022]
Abstract
Over the past two decades, ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, because of treatment-limiting side effects and its additive toxicity with interferon, the search for interferon- and ribavirin-free regimens has been underway. The recent approvals of all-oral direct acting antivirals (DAAs) have revolutionized the HCV therapeutic landscape, and initially it was expected that the role of ribavirin with DAA regimens would be eliminated. On the contrary, what we have witnessed is that ribavirin retains an important role in the optimal treatment of some subgroups of patients, particularly those that historically have been considered the most difficult to cure. Fortunately, it has also been recognized that the safety profile of ribavirin is improved when co-administered with all-oral DAA combinations in the absence of interferon. Despite the antiviral mechanism of action of ribavirin being poorly understood, we now have a range of novel insights into the potential role of ribavirin in all-oral DAA HCV treatment and greater insight into the antiviral mechanism by which it continues to provide clinical benefit for defined patient groups.
Collapse
Affiliation(s)
- Jordan J. Feld
- Toronto Centre for Liver DiseaseToronto General HospitalTorontoONCanada
| | | | | | - Fred Poordad
- Texas Liver InstituteUniversity of Texas Health Science CenterSan AntonioTXUSA
| | | | - Jean‐Michel Pawlotsky
- Department of VirologyNational Reference Center for Viral Hepatitis B, C and DeltaHôpital Henri MondorUniversité Paris‐EstCréteilFrance
- INSERM U955CréteilFrance
| |
Collapse
|
8
|
Affiliation(s)
- Jean‐Michel Pawlotsky
- From the National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Henri Mondor Hospital, Paris‐Est University, Créteil, France; and Unit 955, National Institute of Health and Medical Research, Créteil, France
| |
Collapse
|
9
|
Chevaliez S, Bouvier-Alias M, Dameron G, Darthuy F, Remire J, Pawlotsky J. P.154 Hepatitis virus C RNA quantification by automated COBAS AmpliPrep-COBAS TaqMan 48 (CAP-CTM) real-time PCR assay: An evaluation of performance. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80334-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
10
|
Chevaliez S, Challine D, Brillet R, Pawlotsky J. O.025 Full-length preS1-preS2-HBs antigen (HBsAg) sequence analysis of HBV surface mutants in HBV DNA-positive organ, tissue and cell donors with various HBV serological profiles. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80034-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
11
|
Borroto-Esoda K, Arterburn S, Snow A, Chuck S, Hadziyannis S, Locarnini S, Pawlotsky J, Zoulim F. P.105 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in hepatitis B e antigen-negative patients. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80287-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
12
|
Woerther P, Morice Y, Barbotte L, Montestruc F, Lavillette D, Bouvier-Alias M, Bronowicki J, Hézode C, Lonjon-Domanec I, Bartosch B, Cosset F, Pawlotsky J. P.197 Baseline neutralizing responses predict the virological response to pegylated interferon alpha-ribavirin combination therapy. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80377-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
|